Skip to main content

Clinical Trial Results


Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: Effects Of Interleukin-6 Inhibition With Ziltivekimab On Biomarkers Of Inflammation Among Patients At High Risk For Atherosclerotic Events

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab


Disclosures: TBD